Andrew Muncey
Directeur des opérations chez Artios Pharma Ltd.
Profil
Andrew Muncey was the founder of Acacia Pharma Group Ltd.
(founded in 2007) and Acacia Pharma Ltd.
(founded in 2006), where he held the title of Chief Financial Officer.
He is currently the Chief Operating Officer & Secretary at Artios Pharma Ltd.
since 2016.
Mr. Muncey has previously worked as the Chief Executive Officer at Amura Therapeutics Ltd., Chief Financial Officer at Lorantis Ltd., Principal at PricewaterhouseCoopers LLP (United Kingdom) and Swiss Bank Corp.
(London Branch), and Chief Financial Officer at Bicycle Therapeutics Plc and Kymab Ltd.
Postes actifs de Andrew Muncey
| Sociétés | Poste | Début |
|---|---|---|
Artios Pharma Ltd.
 Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Directeur des opérations | 12/01/2021 |
Anciens postes connus de Andrew Muncey
| Sociétés | Poste | Fin |
|---|---|---|
| BICYCLE THERAPEUTICS PLC | Directeur Financier/CFO | 01/08/2017 |
| ACACIA PHARMA GROUP PLC | Fondateur | - |
| Amura Therapeutics Ltd. | Directeur Général | - |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Directeur Financier/CFO | - |
Lorantis Ltd.
 Lorantis Ltd. Pharmaceuticals: MajorHealth Technology Lorantis Ltd. used to discover and develop drugs. The company had discovered a fundamental immune mechanism, by which the immune response to any disease-causing antigen may be suppressed. It used pursue immunology drug discovery and development programmes to address unmet medical needs. Lorantis was founded in 1998 and was headquartered in Cambridge, UK | Directeur Financier/CFO | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BICYCLE THERAPEUTICS PLC | Health Technology |
| Entreprise privées | 8 |
|---|---|
Lorantis Ltd.
Lorantis Ltd. Pharmaceuticals: MajorHealth Technology Lorantis Ltd. used to discover and develop drugs. The company had discovered a fundamental immune mechanism, by which the immune response to any disease-causing antigen may be suppressed. It used pursue immunology drug discovery and development programmes to address unmet medical needs. Lorantis was founded in 1998 and was headquartered in Cambridge, UK | Health Technology |
PricewaterhouseCoopers LLP (United Kingdom)
 PricewaterhouseCoopers LLP (United Kingdom) Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers LLP engages in the provision of accounting services. Its services include audit and assurance, accounting advisory, risk assurance, tax management, corporate insolvency, life cycle assessment, forensic services, private equity advisory, and financial reporting valuations. The company is headquartered in London, the United Kingdom. | Commercial Services |
| Swiss Bank Corp. (London Branch) | Finance |
Acacia Pharma Ltd.
 Acacia Pharma Ltd. Pharmaceuticals: MajorHealth Technology Acacia Pharma Ltd. develops supportive care product opportunities for post-surgical and cancer patients. It specializes in the discovery and development of cancer supportive care product opportunities based on established drugs. The firm’s product pipeline addresses supportive care indications, such as post-operative and chemotherapy-induced nausea and vomiting, xerostomia and cachexia. The company was founded by Andrew Muncey, Julian Clive Gilbert and Robert William Gristwood in 2006 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
| Amura Therapeutics Ltd. | |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Acacia Pharma Group Ltd.
 Acacia Pharma Group Ltd. Pharmaceuticals: OtherHealth Technology Acacia Pharma Group Plc is a holding company, which engages in the development and commercialization of pharmaceutical product. It focuses on the new nausea and vomiting treatments for surgical and cancer patients. The company was founded by Julian Clive Gilbert, Robert William Gristwood, and Andrew Muncey in 2007 and is headquartered in Duxford, the United Kingdom. | Health Technology |
Artios Pharma Ltd.
Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Health Technology |
